Neoantigens Phase I Trial in Newly Diagnosed Glioblastoma Patients
Status:
Recruiting
Trial end date:
2025-08-12
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the safety and tolerability, feasibility of
the NeoPep Vaccine in newly diagnosed glioblastoma (GB) patients.